Home Technology Pipeline Our Team Contact Us
Developing Next Generation for the treatment of

Senior Management

Neal G. Simon, Ph.D., CEO, has headed Azevan Pharmaceuticals since 1999. Dr. Simon is the former Chair of Biological Sciences at Lehigh University. He has over 25 years research experience in behavioral neurobiology. His research in drug development, hormone-neurotransmitter interactions, and behavioral regulation has been supported by the National Institutes of Health, the National Science Foundation, the Ben Franklin Northeast Tier Technology Partnership, the Life Sciences Greenhouse of Central PA, and the H.F Guggenheim Foundation, and private corporations. He serves on foundation and scientific advisory boards and consults for biotechnology companies. Dr. Simon received a B.A. with honors from the State University of New York at Binghamton, the M.S. and Ph.D. from Rutgers University, and was a National Research Service Postdoctoral Fellow at the State University of New York at Stony Brook. In 1996, he served as a Distinguished Research Professor at Université Louis Pasteur in Strasbourg, France.


Eve M. Damiano, M.S., RAC Sr. VP Operations, has spent over 27 years in the biotechnology industry, focusing on product development and regulatory strategies. Throughout her career, Ms. Damiano has held various professional positions progressing from bench scientist through senior management. Her experience was garnered at companies including Centocor, MedImmune, OraSure Technologies and Vicuron Pharmaceuticals, having served as the Vice President of Regulatory Affairs at the latter two companies. She holds a BS degree from California University of Pennsylvania and a MS degree from The Drexel College of Medicine.


Michael Brownstein, Ph.D., M.D., Vice President Drug Development, earned his bachelor's degree from Columbia University and completed his graduate training at the University of Chicago, where he earned an M.D. and Ph.D. in pharmacology. He received his clinical training at the Boston Children's Hospital and then moved to the National Institutes of Health to work with Julius Axelrod, recipient of a Nobel Prize in 1970 for his studies in the field of neuropharmacology. Dr. Brownstein remained at NIH after completing his fellowship, where he served as Chief of the Laboratory of Genetics of the National Institute of Mental Health and the National Human Genome Research Institute. For two years, he was the Scientific Director of the NIMH Intramural Research Program. While at the NIMH/NHGRI, he directed the Brain Molecular Anatomy Project. Simultaneously, he contributed to the Mammalian Gene Collection, a trans-Institutional effort to clone and sequence cDNAs corresponding to all human, mouse, and rat transcripts. Subsequently he directed the functional genomics program at the J. Craig Venter Institute in Rockville, MD for three years. Currently he is a Scientist Emeritus at the NIH. He has worked in the fields of neurobiology, neuroendocrinology, biochemical pharmacology, genetics, and genomics; has published more than 300 papers in peer reviewed journals; and has served on major editorial boards and continues to serve on a number of scientific advisory boards. Dr. Brownstein also co-founded several successful bio-pharmaceutical companies.